Evidence map›Paper›PMID 26510796›Full record

ReviewRecent patents on endocrine, metabolic & immune drug discovery2015

Adjudin--A Male Contraceptive with Other Biological Activities.

Yan-Ho Cheng, Weiliang Xia, Elissa W P Wong, Qian R Xie, Jiaxiang Shao, Tengyuan Liu, Yizhou Quan, Tingting Zhang, Xiao Yang, Keyi Geng and 2 more

Open access · greenAbstract readReview
In one paragraph

Review in Recent patents on endocrine, metabolic & immune drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yan-Ho Cheng
Weiliang Xia
Elissa W P Wong
Qian R Xie
Jiaxiang Shao
Tengyuan Liu
Yizhou Quan
Tingting Zhang
Xiao Yang
Keyi Geng
Bruno Silvestrini
Chuen-Yan ChengThe Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave, New York, New York 10065, United States of America. Y-Cheng@popcbr.rockefeller.edu.
Population Council · US

Funding

SPECIALIZED CONTRACEPTIVE DEVELOPMENT RESEARCH CENTERU54HD029990 · NICHD · POPULATION COUNCIL · PI WARE, REGINE SITRUK · 1992 to 2016
$27.7M
The biology of blood-testis barrier dynamicsR01HD056034 · NICHD · POPULATION COUNCIL · PI CHENG, C. YAN · 2009 to 2018
$3.4M
NICHD NIH HHS R01 HD056034NICHD NIH HHS U54 HD029990PHS HHS NICHD U54 HD029990
6 · The paper itself

Abstract

backgroundAdjudin has been explored as a male contraceptive for the last 15 years since its initial synthesis in the late 1990s. More than 50 papers have been published and listed in PubMed in which its mechanism that induces exfoliation of germ cells from the seminiferous epithelium, such as its effects on actin microfilaments at the apical ES (ectoplasmic specialization, a testis-specific actin-rich anchoring junction) has been delineated.

objectiveRecent studies have demonstrated that, besides its activity to induce germ cell exfoliation from the seminiferous epithelium to cause reversible infertility in male rodents, adjudin possesses other biological activities, which include anti-cancer, anti-inflammation in the brain, and anti-ototoxicity induced by gentamicin in rodents. Results of these findings likely spark the interest of investigators to explore other medical use of this and other indazole-based compounds, possibly mediated by the signaling pathway(s) in the mitochondria of mammalian cells following treatment with adjudin. In this review, we carefully evaluate these recent findings.

methodsPapers published and listed at www.pubmed.org and patents pertinent to adjudin and its related compounds were searched. Findings were reviewed and critically evaluated, and summarized herein.

resultsAdjudin is a novel compound that possesses anti-spermatogenetic activity. Furthermore, it possesses anti-cancer, anti-inflammation, anti-neurodegeneration, and anti-ototoxicity activities based on studies using different in vitro and in vivo models.

conclusionStudies on adjudin should be expanded to better understand its biological activities so that it can become a useful drug for treatment of other ailments besides serving as a male contraceptive.

Indexed as

AnimalsAnti-Inflammatory AgentsAntineoplastic AgentsContraceptive Agents, MaleHair Cells, AuditoryHumansHydrazinesIndazolesMale1-(2,4-dichlorobenzyl)indazole-3-carbohydrazideAnti-Inflammatory AgentsAntineoplastic AgentsContraceptive Agents, MaleHydrazinesIndazoleslonidamine

Identifiers

PMID26510796
PMCPMC5802880
OpenAlexW2245425663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.